Cue Biopharma, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer , Bayer ’s former chief digital officer a

Who: Cue Biopharma and Ono Pharmaceutical What: The two companies signed a deal to develop and commercialize CUE-401, Cue’s bispecific fusion protein in inflammatory and autoimmune diseases. Why: